Novartis AG Stock News

Novartis (NVS) closed the most recent trading day at $101.37, moving +0.66% from the previous trading session.

With the S&P500 practically at all-time highs, it's no understatement to say that the stock market is booming. From AI to consumer goods, many industries are reporting favorable earnings growth at the

Novartis (NVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Last week saw a rally in Nvidia stock, causing nervousness among value and income investors. There were opportunities to buy quality companies at good or even great valuations even during the tech bub

A new list of 27 new dividend increases, including King Kimberly-Clark and three other champions.

Novartis (NVS) reachead $102.22 at the closing of the latest trading day, reflecting a -0.9% change compared to its last close.

Britain's health regulator said on Wednesday it had revoked a conditional marketing authorisation for Novartis' sickle cell disease drug, Adakveo.

Novartis (NVS) announces an agreement to acquire Germany-based MorphoSys AG and add the latter's late-stage candidate pelabresib to its pipeline.

Novartis (NVS) has struck a deal to buy German biotech firm MorphoSys (MOR), a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), as the Swiss drugmaker expands its roster of cancer

Novartis AG has announced the acquisition of Germany-based cancer drug maker MorphoSys AG through a €2.7 billion deal. Unveiling the takeover on Monday, Novartis said the move would expand its oncol

Novartis AG on Monday announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion).

CNBC's Steve Kovach joins 'Closing Bell Overtime' with breaking news out of the pharmaceutical space.

Drugmaker Novartis AG said on Monday is has acquired MorphoSys AG , a developer of cancer treatments, for 2.7 billion euros. ($2.90 billion)

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has unveiled changes to a seven-year agreement with Novartis Pharmaceuticals for the distribution of its eye treatment. Xiidra, a treatment for dry eye, will b

Fourth-quarter earnings season in Europe is still in its early days, but the largest companies on the Continent are mostly hitting their stride.